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Abstract
Human immunodeficiency virus (HIV) is a chronic infection that can be managed by antire-
troviral treatment (ART). However, periods of suboptimal viral suppression during lifelong
ART can select for HIV drug resistant (DR) variants. Transmission of drug resistant virus
can lessen or abrogate ART efficacy. Therefore, testing of individuals for drug resistance
prior to initiation of treatment is recommended to ensure effective ART. Sensitive and inex-
pensive HIV genotyping methods are needed in low-resource settings where most HIV
infections occur. The oligonucleotide ligation assay (OLA) is a sensitive point mutation
assay for detection of drug resistance mutations in HIV pol. The current OLA involves four
main steps from sample to analysis: (1) lysis and/or nucleic acid extraction, (2) amplification
of HIV RNA or DNA, (3) ligation of oligonucleotide probes designed to detect single nucleo-
tide mutations that confer HIV drug resistance, and (4) analysis via oligonucleotide surface
capture, denaturation, and detection (CDD). The relative complexity of these steps has lim-
ited its adoption in resource-limited laboratories. Here we describe a simplification of the
2.5-hour plate-format CDD to a 45-minute paper-format CDD that eliminates the need for a
plate reader. Analysis of mutations at four HIV-1 DR codons (K103N, Y181C, M184V, and
G190A) in 26 blood specimens showed a strong correlation of the ratios of mutant signal to
total signal between the paper CDD and the plate CDD. The assay described makes the
OLA easier to perform in low resource laboratories.
Introduction
Since human immunodeficiency virus (HIV) was recognized in the 1980s [1], 75 million people
have become infected, of which about half have died of AIDS [2]. In 1996 combination antire-
troviral treatment (ART) was found to control HIV replication and to prolong lives of infected
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individuals [3]. However, lifelong ART is required, and if intracellular drug concentrations fall
to subtherapeutic levels, HIV drug-resistant (DR) strains are selected. Transmission of DR
virus can undermine ART efficacy. Therefore, testing of individuals prior to initiation of treat-
ment is recommended in North America and Europe. HIV infections are most prevalent in
low- to middle-income countries where transmission of resistant viruses have increased over
the past decade [4–9]. In the absence of proper DR screening, the spread of DR HIV can reduce
the durability of available first-line ART [10,11] and as a result there is an urgent need to estab-
lish DR HIV testing prior to initiation of ART internationally [12]. In addition, DR testing in
patients failing first-line therapy may assist in treatment management in low-resource settings,
where available drugs are limited and unnecessary switches to second-line should be avoided.
However clinical trials are needed to assess the value of this approach.
In North America and Europe, consensus sequencing (Sanger) has become the standard
method to screen for HIV drug resistance. A genotype of the HIV pol encoding protease and
reverse transcriptase currently costs US$200-$700, which is unaffordable to most patients in
low- to middle-income countries with the highest prevalence of HIV. In addition, population-
based sequencing only detects DR when the proportion of mutant virus is>15%-30% of the
total viral population [13], while lower proportions can result in treatment failure [14].
Whereas ultra-deep sequencing can detect DR as low as 0.5–1% of the viral population, this
technology is more complex and uses more expensive instruments compared to Sanger
sequencing [15].
Consensus sequencing provides the genotype over the entire HIV pol region amplified,
which may include protease, reverse transcriptase and integrase, and therefore simultaneously
assesses all HIV drug resistance sites within the amplified region. However, in settings where
the availability of antiretrovirals is limited, drug resistance screening can be accomplished by
targeting a small set of specific single nucleotide mutations associated with resistance to antire-
trovirals used in the community.
In 1988, the oligonucleotide ligation assay (OLA) was first developed to diagnose mutations
associated with sickle-cell anemia [16] and was then adapted to detect drug resistance muta-
tions in HIV [17–21]. The OLA has been developed and validated for detection of multiple
HIV mutations associated with resistance to protease and reverse transcriptase inhibitors [17–
19], it is highly sensitive for detection of minority mutant variants (2–5% of an individual’s
HIV population) [21,22], it is tolerant of genetic polymorphisms in clinical specimens [17],
and can be adapted to regional variants [23]. The OLA has been used to study HIV drug resis-
tance in various clinical scenarios in Thailand and Africa [6,24] and currently is being tested in
a clinical trial (clinicaltrials.gov #NCT01898754). OLA takes advantage of probe hybridization
and absolute specificity of ligation to identify a specific base mutation (Fig 1). Two DNA
probes hybridize adjacent to one another, with the 3’-end of the upstream probe annealing to
the site of the mutation of interest. The probes are then covalently linked by a thermostable
ligase only when there is perfect complementation with the template at the mutation site and
adjacent 1–3 bases. Performing the ligation at relatively low temperature (37°C) minimizes the
effects of polymorphisms within the target sequence, while maintaining the specificity at the
site of interest.
Following the ligation step, the ligated probes are detected via surface capture, denaturation
of oligonucleotide from target DNA, and enzyme-based detection (CDD, Fig 2A). Ligation and
CDD are performed after PCR amplification and can be used to target either HIV DNA or
viral RNA. Probe sets specific for the wild-type (WT) and the mutant (MUT) genotypes pro-
vide estimates of their relative proportion that is comparable to quantification by 454-pyrose-
quencing [22].
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The OLA-based DR HIV test offers an attractive cost (<$5.00 per codon) and a higher sen-
sitivity compared to Sanger sequencing. However, the duration and complexity of the proce-
dure, in particular the CDD procedure, has made it difficult to transfer OLA to resource-
limited laboratories [17]. The goal of this work was to simplify the CDD procedure by adapting
it to a paper strip format (Fig 2B). The CDD chemistry was directly transferred onto the paper
format with modifications that reduced the number of steps and total assay time, and allowed
visual detection of results. The paper-format CDD was used to identify mutants at four com-
mon HIV DR codons in a blinded set of blood specimens, and the results were compared to
results obtained with the current plate CDD.
Materials and Methods
Study design and specimens
Leftover blood specimens from HIV-infected Kenyans collected as part of an observational
study of transmitted drug resistance conducted in Kenya in 2010 (unpublished) were tested
and analyzed for a retrospective study approved by Human Subjects Protection Committees at
Seattle Children’s Hospital and Kenyatta National Hospital. Specimens collected over a period
of 2–12 month from subjects with virologic failure of first-line ART were selected based on pre-
vious testing by the current plate-format OLA. The selected specimens included HIV subtypes
A (N = 8), C (N = 1), D (N = 5), AE (N = 9) and G (N = 3), and one or more drug resistance
mutations at four codons in HIV reverse transcriptase (K103N, Y181C, G190A and M184V)
Fig 1. Schematic of amplification and ligation in the existing oligonucleotide ligation assay (OLA). The pol gene of HIV DNA is amplified by nested
PCR. Note that the HIV DNA gene map positions are not to scale. A portion of the amplicon is mixed with three oligonucleotide probes: a 5’ fluorescein (F)
-conjugated mutant (MUT)-specific HIV probe; a 5’ digoxigenin (D) -conjugated wild-type (WT)-specific probe; and a 5’ phosphorylated, 3’ biotin (B)
-conjugated common probe. When specific probes are complementary at the mutation site, they are ligated to the common probe to create a DNA strand with
labels at both ends. Only ligated products are detected during the CDD procedure (surface capture, denaturation of oligonucleotide from target DNA, and
enzyme-based detection).
doi:10.1371/journal.pone.0145962.g001
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spanning a wide range of frequencies in each subjects’HIV population. The paper CDD was
compared to plate CDD by testing the same set of PCR amplicons from participant specimens
as well as plasmid standards containing the mutations of interest. The probe hybridization and
ligation step was performed separately and at different times for the plate and paper CDD
using the same protocol and reagents. Laboratory personnel were “blinded” to the mutational
content of each specimen during testing of the paper CDD.
DNA extraction
Participant’s PBMCs were isolated from 10mL whole blood by gradient centrifugation in His-
topaque (Sigma, 1077, St. Louis, MO). Genomic DNA was then extracted from frozen PBMC
pellets (~ 5x106 cells) using a DNA Archive Pure DNA Purification System (5 PRIME, Inc.,
Gaithersburg, MD).
Fig 2. Plate and paper formats for Capture, Denaturation and Detection (CDD) in the oligonucleotide ligation assay. (A) Plate CDD procedure.
Products from the ligation step (both ligated and non-ligated products) are captured on a streptavidin-coated plate. Non-ligated probes are released during
oligonucleotide denaturation, and ligated MUT andWT probes are then detected in sequential enzyme-based immunoassays (labeling by different detection
antibodies, alkaline phosphatase yellow substrate development, optical density reading at 405nm, wash steps, tetramethylbenzidine (TMB) development,
stop solution, and optical density reading at 450nm). (B) Paper CDD procedure. Similar to the plate CDD procedure, products from the ligation step (both
ligated and non-ligated products) are captured. However, here the products are captured on paper strips by immobilized streptavidin. Non-ligated probes are
released during oligonucleotide denaturation. Antibodies targeting the end-labels of the mutant (MUT) or wild-type (WT) probes have conjugated horseradish
peroxidase (POD) that converts 3,3’ diazoaminobenzidine substrate (DAB) into brown precipitates. Signals were captured by the scanner (600 DPI).
Reported signals represent capture spot intensity minus a background region from the strip.
doi:10.1371/journal.pone.0145962.g002
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PCR amplification of HIV pol
Clinical specimens. A 1009 bp region of the pol gene was amplified by nested PCR.
Two μg of each DNA were added to a 50μl reaction mixture containing 400nM of forward
(5’-CCT ACA CCT GTC AAC ATA ATT GG-3’) and reverse primers (5’-AAC TTC TGT
ATA TCA TTG ACA GTC CA-3’), 200μM dNTPs, 3mMMgCl2, and 2.5U of MyTaq
TM DNA
polymerase (Bioline USA, Inc., Taunton, MA). Cycling conditions included a denaturation
cycle of 5 minutes at 94°C and 35 cycles of 30 seconds at 94°C, 30 seconds at 55°C, and 1 min-
ute at 72°C, followed by an extension step of 7 minutes at 72°C. Nested PCR was performed by
adding 2μl of first round amplicon to a 50μl reaction mixture containing 400nM of inner for-
ward primer (5’-CAA ATC ACT CTT TGG CAR CGA CC-3’) and inner reverse primer (5’-
CAY TTG TCA GGA TGG AGT TCA TA-3’), 200μM dNTPs, 3mMMgCl2, and 2.5U of
MyTaq DNA polymerase. Second round cycling conditions were the same as the first round,
except the extension time was reduced to 30 seconds. Second-round PCR products were visual-
ized by electrophoresis on 1% agarose gels (LE Quick Dissolve Agarose, GeneMate, Kaysville,
UT) in SB buffer (5mM sodium tetraborate decahydrate).
Plasmid standards. Plasmid DNA containing patient-derived HIV pol sequences with
mutations at codons of interest served as standards. Plasmid standards for each of the four
codons tested were prepared by mixing mutant (MUT) plasmid with wild-type (WT) plasmid
(concentrations of 0%, 5%, and 50%MUT). Plasmid standards (0.1ng) were amplified in a 50μl
reaction mixture containing forward and reverse M13 primers using the same reagents and
conditions as the second round PCR used for clinical specimens. PCR products were visualized
by agarose gel electrophoresis.
Ligation
Sequences and concentrations of ligation probes (S1 Table) for each mutation tested were opti-
mized for HIV subtypes prevalent in Kenya (A, D and C). Ligation reactions were carried out
in separate wells for each codon to avoid competition between overlapping probes. DNA
amplicons were diluted 1:4 in nuclease-free water (Promega, P1193, Madison, WI). Two μl of
diluted DNA were added to 20μl reaction mixture containing: 0.67U of thermostable Ampli-
gase ligase (Epicentre Technology, A3210K, Madison, WI), 12.5mM KCl, 1mMNAD (Sigma,
7004, St. Louis, MO), 1X ligase buffer (20mM Tris pH 8.0, 10mMMgCl2, 1mM DDT),
0.1075% Triton-X 100, and the oligonucleotide probes specific for each mutation tested (Inte-
grated DNA Technology, Coralville, IA). The mixture was subjected to 10 cycles of 94°C for 30
seconds, followed by 37°C for 4 minutes, followed by inactivation of the ligase enzyme by addi-
tion of 10μl of 100mM EDTA/0.1% Triton X-100.
Oligonucleotide Capture, Denaturation, and Detection (CDD)
Plate-format CDD. The product from the ligation step (32μL) was transferred to a strep-
tavidin-coated 96-well microtiter plate (Sigma, 1173477600, St. Louis, MO)) and covered with
an adhesive seal and incubated for one hour at room temperature without being shaken. The
plate was then washed twice with 1X denaturing buffer (0.01N sodium hydroxide, 0.05%
Tween-20) followed by two washes with 1X neutralization buffer (100mM Tris pH 7.5, 150mM
sodium chloride, 0.05% Tween-20). Fifty μl of an antibody mixture (37.5mU anti- fluorescein-
alkaline phosphatase (AP) Fab fragments (Roche, 11426338910, Indianapolis, IN) and 7.5mU
anti-digoxigenin-peroxidase (POD) Fab fragments (Roche, 11207733910, Indianapolis, IN) in
1X Phosphate Buffered Saline (1X PBS) with 0.5% Bovine Serum Albumin (Sigma, A6793,
St. Louis, MO) was added to each well and incubated for 30 minutes at room temperature in
the dark. The plate was then washed six times with 1X neutralization buffer. Subsequently,
Simplified Paper for Detecting HIV Drug Resistance by OLA
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100μl of alkaline phosphate yellow liquid substrate (Sigma, P7998, St. Louis, MO) were added
and incubated until the yellow color developed fully (20 to 35 minutes, depending on the muta-
tion tested), and the optical density (OD) was read at 405nm (SpectraMax 190, Molecular
Devices, Sunnyvale, CA) to measure the MUT signal level. The plate was then washed six times
with 300μl of 1X neutralization buffer, and 50μl of tetramethylbenzidine (TMB) One Solution
(Promega, G7431, Madison, WI) were added to each well. After 3–5 minutes at room tempera-
ture, 50μl of 0.3M H2SO4 were added to each well to stop the reaction. The OD was read at
450nm to measure the WT signal level.
The WT OD or MUT OD (range: 0–4 A.U.) for each specimen was calculated from the OD
of the sample wells minus the average OD of the blank wells (enzyme substrates only). The WT
OD and MUT OD from a sample was then converted to a single value as MUT Ratio (MUT
OD/(MUT OD +WT OD)), in order to account for rare cases of differential probe-binding
efficiency between plasmid standards and clinical specimens [22]. The MUT Ratios of all plate
CDD experiments are summarized in S2 Table.
Paper-format CDD. AMylar-backed nitrocellulose membrane (EMDMillipore, High-
Flow Plus 13504XSS, Billerica, MA) was cut into 3mm x 25mm strips using a CO2 laser cutter
(Universal Laser Systems, Scottsdale, AZ) at 5% speed, 5% power, and 1000 pulses per inch.
The strips were hand-spotted with 1μl of 1mg/ml streptavidin (Sigma, S-0677, St. Louis, MO)
in 1X PBS (Corning, 21-040-CV, Manassas, VA), incubated 2 hours at 37°C (Thermo Forma
Water Jacketed CO2 incubator), and kept dried in a desiccator (Bel-Art 42073100, Wayne, NJ)
at 20% humidity, 22–25°C. A cellulose absorbent pad (EMDMillipore, CF22300, Billerica,
MA) was attached to the nitrocellulose strips with a 3-mm overlap via an adhesive plastic back-
ing (10 mil Melinex with adhesive on 1 side, Fraylock, San Carlos, CA).
Paper devices were used within 3 days of reagent spotting. The strips were dipped in a timed
sequence (5 minutes each) in a series of untreated polystyrene 96-well microtiter plate (Sigma,
P7491-1CS, St. Louis, MO) containing the following reagents: (1) 25μl 1% BSA/1X PBS buffer
(Bovine Serum Albumin–Sigma, A3059-1006, St. Louis, MO), (2) 27.5μl ligated products, (3)
25μl 10X denaturing solution (0.1N sodium hydroxide with 0.05% Tween-20), (4) 25μl 1X neu-
tralizing buffer, (5) 25μl of labeling antibodies (3.75U of anti-digoxigenin-POD (Roche,
11207733910, Indianapolis, IN) for WT detection or anti-fluorescein-POD (Roche,
11426346910, Indianapolis, IN) for MUT detection), (6) 25μl of 1X PBS with 0.05% Tween-20
(PBST), (7) 40μl of signal amplification reagent (250μg/ml 3,3’-diaminobenzidine (DAB), KPL,
710008, Gaithersburg, MD) with 250μg/ml w/v sodium percarbonate (Sigma, 371432,
St. Louis, MO) in 1X PBST, and (8) 25μl of 1X PBST. Wet strips were immediately imaged (48
BitHDR, 600dpi, non-gamma corrected, no filter) using a flatbed scanner (Epson V700, Long
Beach, CA) and SilverFast software (LaserSoft Imaging, Sarasota, FL). The humidity and tem-
perature during the experiments were not controlled but were measured (45–50% humidity
and 22–25°C). The WT and MUT signals were extracted from scanned images of the paper
strips using in-house codes written in MATLAB (MathWorks, Natick, MA). Intensity of each
pixel from the capture spot (specimen) and a region upstream of the capture spot (background)
were extracted from two regions of interest (ROIs) of equal size (55 x 40 pixels, 2.32mm x
1.70mm). The reported signal intensity was calculated as the 95th percentile of the intensity in
the capture spot ROI minus the 95th percentile of the background ROI. S3 Table provides the
detailed calculation and the MATLAB code. The MUT Ratio from a sample evaluated by paper
CDD was calculated fromMUT signal intensity/(MUT signal intensity + WT signal intensity).
The MUT Ratios of all paper CDD experiments are summarized in S4 Table.
Simplified Paper for Detecting HIV Drug Resistance by OLA
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Results
In the current OLA using the plate-format CDD, conditions are optimized to obtain a sensitive
MUT response to samples with low %MUT, while the WT assay gives saturated signals in the
range of 0–50%MUT to serve as a positive control for successful ligation and detection. To
investigate the analytical response of OLA using the paper CDD, a plasmid mixture dilution
series for the Y181C mutation (0, 2, 5, 10, 25, 50, 75, 100%MUT) was tested for MUT andWT
responses and compared to the signals obtained with the plate CDD (Fig 3). The paper CDD
showed strong MUT signal for 2% MUT, but its signal saturated at a lower % MUT than in the
plate CDD (Fig 3A and 3B). The paper CDD showed strong WT signals across the full dilution
series, as in the plate CDD (Fig 3B). Correlation plots of MUT data in Fig 3A, WT data in Fig
3B, and MUT Ratios from plate CDD and from paper CDD are shown in S1 Fig.
Clinical specimens (N = 26) fromKenyan’s infected with HIV-1 subtypes A, C, D, AE and G,
and plasmid standards at 0, 5 and 50%MUTwere tested for drug resistance mutations at four HIV
codons (K103N, Y181C, M184V and G190A, N total = 104) by both paper CDD and plate CDD
OLA (Figs 4 and 5). At low %MUT, theMUT assay showed a linear correlation between both CDD
formats for specimens, while signal saturated in the paper CDD at high %MUT (S4A–S4D Fig).
TheWT assay showed strong responses for most specimens and plasmid standards in both formats
(S4E–S4H Fig). For all codons combined, the MUT Ratios for paper CDD and plate CDD correlate
strongly across participants’ data (Fig 6). The polynomial fit of data is shown in S4I–S4K Fig.
Discussion
In this work, the detection procedure (i.e., CDD) of the OLA-based DR HIV test was simplified
to enhance adoption in low-resource settings. The primary modification was conversion of
Fig 3. Comparison of paper Capture, Denaturation, and Detection (CDD) and plate CDD for analysis of a plasmid standard mixture series for
mutation Y181C. (A) Scanned images of paper CDDMUT (left) andWT (right) detection (B) Mutant (MUT) detection (C) wild-type (WT) detection. Left axes:
Specimen optical density (OD) minus negative control OD analyzed in duplicate by plate CDD (mean ± SE). Right axes: Specimen capture intensity minus
background intensity analyzed in triplicate by paper CDD (mean ± SE). The ratio of mean signal intensities for 2%MUT and 0%MUT was 2.00 for plate CDD
and 2.74 for paper CDD.
doi:10.1371/journal.pone.0145962.g003
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Fig 4. Analysis of clinical specimens and plasmid standards by paper capture, denaturation, and
detection (CDD) and plate CDD for mutations K103N and Y181C. Panels A and C showmutant (MUT)
detection, and Panels B and D show wild-type (WT) detection. Sample optical density (OD) minus negative
control OD (left y axis) for each specimen is shown in white/gray by rank along the x axis, from the lowest
MUT OD, followed by the plasmid standards (0%, 5%, 50%MUT) performed in duplicate. Spot intensity
minus background intensity (right y axis) for each specimen is shown in blue and green bars followed by the
plasmid standards (0%, 5%, 50%MUT) performed in triplicate. Scanned images of the paper CDD detection
strip are shown below each specimen’s signal data.
doi:10.1371/journal.pone.0145962.g004
Simplified Paper for Detecting HIV Drug Resistance by OLA
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Fig 5. Analysis of clinical specimens and plasmid standards by paper capture, denaturation, and
detection (CDD) and plate CDD for mutations M184V and G190A. Panels A and C showmutant (MUT)
detection, and Panels B and D show wild-type (WT) detection. Sample optical density (OD) minus negative
control OD (left y axis) for each specimen is shown in white/gray by rank along the x axis, from the lowest
MUT OD, followed by the plasmid standards (0%, 5%, 50%MUT) performed in duplicate. Spot intensity
minus background intensity (right y axis) for each specimen is shown in pink and orange bars followed by the
Simplified Paper for Detecting HIV Drug Resistance by OLA
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CDD from a plate format to a paper strip format. Exploiting rapid capture and labeling in
paper reduced reaction time for all binding steps (5 minutes each). Instead of two-stage enzy-
matic labeling for WT and MUT detection used in the plate OLA, we simultaneously detected
WT and MUT using the same enzyme system (i.e., POD) in parallel strips (with the same tim-
ing of steps). Additionally, use of a precipitating substrate (i.e., DAB) created visible spots. This
eliminates the need for a spectrophotometer to determine the threshold signal for a positive
reaction and to estimate the proportion of mutant in subjects’ specimens.
The plate CDD uses streptavidin-coated well plates to capture ligation probes and a dena-
turing buffer to remove non-ligated probes from template DNA. In the paper OLA, streptavi-
din was immobilized onto nitrocellulose strips via spotting and drying. We found that a more
stringent denaturing buffer (10X compared to plate CDD) was needed to achieve low back-
ground (S2 Fig). The 10X denaturing buffer did not strip streptavidin from the nitrocellulose
(S3A Fig, One-Way ANOVA, α = 0.05), and had little impact on its ability to capture a biotiny-
lated target (S3C Fig, statistically significant but small effect).
The paper strip format reduced the time needed to perform the assay. Typical plate assays
require long incubation steps for target capture and labeling, due in large part to slow diffusion
of probes and other reagents to the plate capture surface. In contrast, delivery by flow in paper
provides intimate contact of reagents with the detection surface, as targets and labels diffuse
rapidly across the small pores (mean of 2.8μm [25]). As a result, capture and labeling of ligated
products could be completed within 5 minutes each in the paper CDD, compared to long incu-
bations (1-hour and 30-minute incubations, respectively) in the plate CDD.
plasmid standards (0%, 5%, 50%MUT) performed in triplicate. Scanned images of the paper CDD detection
strip are shown below each specimen’s signal data.
doi:10.1371/journal.pone.0145962.g005
Fig 6. Correlation plot of MUT Ratios determined by paper capture, denaturation, and detection (CDD)
versus plate CDD.MUT andWT signals obtained by paper and plate CDD format OLA at codons K103N,
Y181C, M184V and G190A from 26 clinical specimens were used to calculate MUT Ratios. The overall shape
reflects the signal saturation of the paper CDD at high MUT concentration, as seen in Figs 3–5. Results
correlate strongly across clinical specimens and plasmid standards’ data (see S4 Fig for fitted correlation).
doi:10.1371/journal.pone.0145962.g006
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In the plate CDD, the POD system produces detectable signal much faster (5 minutes) than
the AP system (15–45 minutes), and the two detection steps for MUT andWT are performed
sequentially in a single well. To improve speed of detection in the paper format, a single
enzyme system (POD) was used to label MUT and WT probes in parallel strips run simulta-
neously using the same procedure. TMB is the most common substrate for POD-based plate
assays, but it requires addition of H2SO4 to stop the reaction prior to reading [26], and the solu-
ble TMB product [27] would be washed away in the paper CDD. DAB is extensively used to
measure peroxidase activity in tissues [28]; it has only one oxidation state (does not require
post-treatment to fix the color) and forms visible brown precipitate at the detection spots on
the paper strip. The replacement of AP by POD for MUT detection and the use of DAB sub-
strate likely caused the differences between the plate and paper signal saturation seen with all
specimens and standards. The oligonucleotide probe concentrations had been optimized in the
plate CDD for the slower AP-yellow substrate system, and probe concentrations were not
adjusted in the paper CDD. However, a linear correlation can likely be achieved in the paper
CDD by adjusting the concentrations of oligonucleotide probes. If detection of low MUT HIV
levels is needed to predict treatment failure, tuning CDD for strong low-level response may be
desirable.
The relatively large SD values on the standard control samples were greater for codons 103
and 181 compared to 184 and 190. The small number of standard control samples (triplicate)
was sensitive to variation, and the variability in these experiments was likely due to manual
spotting of the paper strips instead of controlled strip preparation. Controlled strip preparation
(e.g., lateral flow striper) is expected to reduce the variability. Overall, the paper CDD showed
analytical sensitivity comparable to the plate CDD for a plasmid mixture series (Y181C, Fig 3
& S4I Fig), and results for clinical specimens showed strong concordance across four relevant
DR codons (Fig 6 & S4J Fig).
While we did not attempt to evaluate % MUT quantification here, our results suggest a
quantitative correlation with plate CDD, which correlates strongly with proportions of mutant
in the HIV population as measured by Roche’s 454 pyrosequencing [22]. In addition, drug
resistance surveillance and treatment monitoring requires a test that targets all DR mutations
prevalent in the patient population. Here, we tested three common nevirapine- and one lami-
vudine-resistance mutations currently prevalent in Kenya [10]. With the availability of new
drug choices for first-line ART, additional DR mutations such as K65R will likely be needed to
more comprehensively assess transmitted and selected HIV DR. The clinical utility of the test
will require evaluation based on available treatment options. Notably, the paper CDD is
expected to translate well to new DR mutations since the capture and detection chemistries are
not target-dependent. OLA can be performed on amplicon derived from either plasma viral
RNA or cellular DNA (PBMC, whole blood, dried blood spots) [17–20]. In this study, we used
PBMC DNA as the HIV DR target as DNA-based assays offer several advantages over RNA,
such as cost savings from reverse transcriptase enzyme and easier handling and processing (no
need for RNAse-free reagents and plastic/glass ware). In addition, for pre-ART testing of DR,
DNA is adequate and can detect archived resistance mutations no longer detectable in plasma
[21,29]. However, testing for DR in plasma RNAmay be more sensitive in patients with early
rebound viremia. The existing plate CDDmeasures WT and MUT in sequential reactions
within a single well. In the paper CDD, we separated the WT and MUT detection into two
strips run in parallel. This reduced the protocol time and complexity, but a procedural control
may be needed to ensure the validity of each strip.
The modifications developed here simplified the CDD steps and reduced the total time.
Both plate and paper CDDs share the upstream processes (DNA extraction, amplification, and
ligation), which take 420min. Paper CDD reduced the total OLA time from 420min plus
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150min/ 1 DR codon to 420 min plus 45 min/ 1 DR codon. The costs for the complete OLA
processes with plate and paper CDDs are comparable (~ $5/codon, S5 Table). Note that the
costs reported represent batching of 36 and 9 samples for plate and paper CDDs, respectively.
More potential simplifications on paper CDD can be done. For example, the CDD reagents
could be stored dry without refrigeration and supplied in wells, as reagent pads integrated into
strips [30] similar to conventional lateral flow tests, or printed directly onto the strip [31].
Long-term storage of some CDD reagents have been demonstrated: DAB substrate [32], POD-
conjugated antibodies [33,34]. While the paper CDD presented here requires manually moving
the paper strips between wells every 5 minutes, there is potential to automate the timed steps
required in the CDD protocol. Paper-microfluidic tools such as dissolvable sugar time delays
[35], shunt time delay valves [36,37], and capillary-based paper networks [38,39] could enable
automation of the protocol presented here. Increasing simplicity of the paper CDD through
dry reagents and automation of the protocol is the subject of current work.
Finally, here we addressed only the CDD portion of the assay, but specimen preparation,
amplification, and ligation still require laboratory procedure and tools, including a thermal
cycler. However, the CDD procedure has been the most difficult portion of the OLA procedure
to transfer to new laboratories, and simplifications to CDD al one should improve access to
OLA. Future work also includes simplification and improvement of other steps in OLA, for
example, nucleic acid extraction and concentration to improve assay sensitivity for low HIV
copy samples as well as isothermal amplification and ligation to avoid the need for a thermal
cycler.
Conclusions
A simple low-cost test for HIV DR could improve efficacy of global ART programs, allow bet-
ter control of the HIV pandemic, reduce the selection and transmission of drug resistance, and
prolong the usefulness of limited drug regimens in resource-constrained regions. The OLA
allows identification of HIV drug resistance at a lower cost and higher sensitivity than Sanger
sequencing, but the complexity of the protocol has been an obstacle for implementation. We
have reduced the time and complexity of the most complex step of the OLA–the detection pro-
cedure. The paper CDD offered more than a three-fold reduction in procedure time (2.5 hours
to 45 minutes) and a reduction in procedure complexity, while yielding performance compara-
ble to the current plate CDD for detection of DR HIV in clinical specimens. While the paper
CDD still relies on procedures and instruments for amplification and ligation, the simplifica-
tion of the detection protocol presented here could allow easier transfer of the OLA to middle-
tier to low-tier laboratories, where resources are more limited.
Supporting Information
S1 Fig. Correlation plots of paper capture, denaturation, and detection (CDD) and plate
CDD for analysis of plasmid standard mixtures for mutation Y181C. (A) Optical density
(OD) of MUT from plate CDD versus intensity of MUT from paper CDD (B) OD of WT
detection from plate CDD versus intensity of WT detection from paper CDD (C) MUT ratio
from plate CDD: ODMUT/(ODWT + ODMUT) versus MUT ratio from paper CDD: inten-
sity MUT/(intensity MUT + intensity WT).
(EPS)
S2 Fig. Denaturing of non-ligated probes to remove background. (A) Schematic of efficient
oligonucleotide denaturing. DNA target is completely dissociated from probes and false signal
is not detected. (B) Schematic of inefficient oligonucleotide denaturing. Non-ligated probes
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bound to target template DNA can be detected, contributing to false signal. (C) Comparison of
denaturing methods. 1X and 10X concentration of denaturing buffer were tested for their abil-
ity to denature non-ligated probes from target template DNA compared to a 1X PBST control.
To generate complete non-ligated probes, a 0% mutant (MUT) plasmid standard of Y181C
was mixed with probes and subjected to 10 cycles of ligation in the absence of ligase enzyme.
1X denaturing buffer was not effective at reducing background (11% reduction), but the 10x
denaturing buffer was effective (94% reduction).
(EPS)
S3 Fig. On-paper oligonucleotide capture by immobilized streptavidin. (A) Streptavidin
presence on membrane after 1X PBST or 10X denaturing buffer wash. The presence of strepta-
vidin immobilized on nitrocellulose was visualized by Ponceau S solutions (10 minutes in Pon-
ceau S solution and 5 minutes in distilled water). The wet strips were scanned and analyzed.
The plot represents signal intensity of stained streptavidin in each case (mean ±SE, n = 4).
There was no significant different between means (one-way ANOVA, p = 0.07) (B) Determina-
tion of linearity of biotin-conjugated-POD (biotin-POD) concentrations captured by on-paper
streptavidin. Biotin-POD was used as a model analyte to quantify capture performance. 25μL
of 10-fold serial dilutions of biotin-POD/ PBST (6.25pg to 62.5μg) was used as a model analyte
(n = 4). The strips were dipped in a timed sequence (5 minutes each) in polystyrene wells con-
taining the following reagents: (1) 25μL of biotin–POD, (2) 25μL of PBST wash, (3) 40μL of
DAB substrate, and (4) 25μL of PBST wash. Wet strips were scanned and analyzed. The plot
represents signal intensity (mean ± SE, n = 4). The linear range was estimated as 0.1–10μg of
biotin-POD, and 625ng of biotin-POD was chosen for the experiment in C (such that an effect,
if present, would be observed by a change in signal intensity). (C) Effect of denaturing buffer
on the ability of immobilized streptavidin to capture biotin-POD. The strips were dipped in a
timed sequence (5 minutes each) in a series of polystyrene wells containing the following
reagents: (1) 25μL of 1X PBST, 1X denaturing buffer, or 10X denaturing buffer, (2) 25μL of
neutralizing buffer (twice), (3) 25μL of 625ng of biotin-POD (within the responsive range from
panel B), (4) 25μL of PBST, (5) 40μL of DAB substrate, and (6) 25μL of PBST. On-paper strep-
tavidin after 10X denaturing buffer yielded significantly lower signal intensity than the ones
treated with PBST or 1X denaturing buffer (One-way ANOVA, Post-hoc comparison (Tukey
Kramer test, α = 0.05).
(EPS)
S4 Fig. Correlation Plots. (A)-(D) MUT signal between paper CDD and plate CDD for the
data in Figs 4A & 3C and 5A & 4C, respectively. (E)-(H) WT signal between paper CDD and
plate CDD for the data in Figs 4B & 4D and 5B & 5D, respectively. (I) Correlation plot of
Y181C Mutant (MUT) Ratios for 26 subjects’HIV DNA compared to the plasmid mixtures
(0%–100% Y181CMUT) and specimen. (J) Correlation plot of MUT Ratios for all four HIV-
drug-resistance codons determined by paper capture, denaturation, and detection (CDD) ver-
sus plate CDD as presented in Fig 6. In both plots, a polynomial fit was used to report R2 values
for the correlations. (K) Explanation of the non-linear curve in B. For samples containing low
% mutant (zone 1), the MUT signals dominated the MUT Ratios because the WT signals were
saturated in both plate and paper CDDs. Paper CDD is more sensitive at low % mutant than
the plate CDD, and this results in a slope>1. The MUT signal of paper CDD reached the satu-
ration earlier than the plate CDD, which causes a plateau-like region (zone 2). As WT signals
were less saturated in samples with high % mutant, the slope increases (zone 3).
(EPS)
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S1 Table. Oligonucleotide probe sequences and concentration in ligation.
(EPS)
S2 Table. Quantitative data of signal ratios of plasmid standards and clinical specimens
evaluated by plate capture, denaturation, and detection (CDD).
(EPS)
S3 Table. Calculation of signal intensity in paper CDD and MATLAB code for image analy-
sis. Red, green, and blue pixels of the image were first projected onto an L-2 vector [0.684
0.1705 0.792], which was developed by linear discriminate analysis to best separate the color of
DAB signal from its background on nitrocellulose, and signals were reported as intensity
(range: 0–30.5 x 216A.U., Eq 1). The reported signal intensity is calculated using Eq 2.
½intensityð55 x 40Þ x 1 ¼ ½ROI pixel intensityð55 x 40Þ x 3  ½L 2 unit vector3 x 1 ðEq 1Þ
signal intensity
¼ 95th percentile of ½intensitybackground  95th percentile of ½intensitysignal ðEq 2Þ
(EPS)
S4 Table. Quantitative data of signal ratios of plasmid standards and clinical specimens
evaluated by paper capture, denaturation, and detection (CDD).
(EPS)
S5 Table. Comparison of time, cost and instrument requirements for plate and paper
CDDs as well as the other steps in OLA.
(EPS)
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